Pages that link to "Q28240662"

The following pages link to A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief (Q28240662):

Displaying 158 items.

• Anti-nerve growth factor in pain management: current evidence (Q26746194) (← links)
• Inhibition of mechanical allodynia in neuropathic pain by TLR5-mediated A-fiber blockade (Q27314839) (← links)
• Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion (Q27332195) (← links)
• Advances in understanding itching and scratching: a new era of targeted treatments (Q28071549) (← links)
• Exacerbating factors of itch in atopic dermatitis (Q28075828) (← links)
• Neuroimmune interactions in itch: Do chronic itch, chronic pain, and chronic cough share similar mechanisms? (Q28083464) (← links)
• Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7 (Q28270611) (← links)
• Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief (Q28273870) (← links)
• Global Nav1.7 knockout mice recapitulate the phenotype of human congenital indifference to pain (Q28542818) (← links)
• Modeling nociception in zebrafish: a way forward for unbiased analgesic discovery (Q28543016) (← links)
• Inhibition of Inactive States of Tetrodotoxin-Sensitive Sodium Channels Reduces Spontaneous Firing of C-Fiber Nociceptors and Produces Analgesia in Formalin and Complete Freund's Adjuvant Models of Pain (Q28548202) (← links)
• Evaluation of recombinant monoclonal antibody SVmab1 binding to Na V1.7 target sequences and block of human Na V1.7 currents (Q28587362) (← links)
• Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release (Q28601095) (← links)
• Information processing in the CNS: a supramolecular chemistry? (Q28607744) (← links)
• New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain (Q30235132) (← links)
• Toll-like receptor 4 contributes to chronic itch, alloknesis, and spinal astrocyte activation in male mice (Q30785636) (← links)
• Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor (Q33390819) (← links)
• β-arrestin-2 regulates NMDA receptor function in spinal lamina II neurons and duration of persistent pain (Q33814944) (← links)
• Affimer proteins are versatile and renewable affinity reagents (Q33842511) (← links)
• Defining the nociceptor transcriptome (Q34487175) (← links)
• Bacterial voltage-gated sodium channels (BacNa(V)s) from the soil, sea, and salt lakes enlighten molecular mechanisms of electrical signaling and pharmacology in the brain and heart (Q34778955) (← links)
• A surface plasmon resonance approach to monitor toxin interactions with an isolated voltage-gated sodium channel paddle motif. (Q35014380) (← links)
• Reduction of Neuropathic and Inflammatory Pain through Inhibition of the Tetrahydrobiopterin Pathway (Q35797434) (← links)
• Temporal dynamics of anxiety phenotypes in a dental pulp injury model (Q35803593) (← links)
• Role of anoctamin-1 and bestrophin-1 in spinal nerve ligation-induced neuropathic pain in rats. (Q35805234) (← links)
• Novel sodium channel antagonists in the treatment of neuropathic pain. (Q35843983) (← links)
• Recent Trends in the Discovery of Small Molecule Blockers of Sodium Channels. (Q36018974) (← links)
• Matrix Metalloproteinase (MMP) Proteolysis of the Extracellular Loop of Voltage-gated Sodium Channels and Potential Alterations in Pain Signaling (Q36281738) (← links)
• A monoclonal antibody against KCNK9 K(+) channel extracellular domain inhibits tumour growth and metastasis (Q36548721) (← links)
• Transient Receptor Potential Vanilloid 4 Ion Channel Functions as a Pruriceptor in Epidermal Keratinocytes to Evoke Histaminergic Itch. (Q36876222) (← links)
• Peripheral Brain Derived Neurotrophic Factor Precursor Regulates Pain as an Inflammatory Mediator (Q36959399) (← links)
• Disrupting the dynamic equilibrium of ORAI channels determines the phenotype of malignant cells (Q36997514) (← links)
• Engineering Highly Potent and Selective Microproteins against Nav1.7 Sodium Channel for Treatment of Pain (Q37065681) (← links)
• Sodium channel Nav1.7 expression is upregulated in the dorsal root ganglia in a rat model of paclitaxel-induced peripheral neuropathy (Q37318012) (← links)
• MicroRNA-30b regulates expression of the sodium channel Nav1.7 in nerve injury-induced neuropathic pain in the rat (Q37368204) (← links)
• Hierarchical CRMP2 posttranslational modifications control NaV1.7 function (Q37549939) (← links)
• No gain, no pain: NaV1.7 as an analgesic target (Q38238866) (← links)
• The voltage-gated sodium channel: a major target of marine neurotoxins (Q38259139) (← links)
• Discovery of functional antibodies targeting ion channels (Q38282832) (← links)
• New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics (Q38289992) (← links)
• Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications (Q38451134) (← links)
• Emerging targets in treating pain (Q38531133) (← links)
• Structural and genetic diversity in antibody repertoires from diverse species (Q38549871) (← links)
• Toward a Mechanism-Based Approach to Pain Diagnosis (Q38559303) (← links)
• NaV1.9: a sodium channel linked to human pain (Q38560993) (← links)
• Afferent hyperexcitability in neuropathic pain and the inconvenient truth about its degeneracy. (Q38585556) (← links)
• The voltage-gated sodium channel NaV 1.9 in visceral pain (Q38606237) (← links)
• Combining Human and Rodent Genetics to Identify New Analgesics (Q38699127) (← links)
• Functional Studies of Sodium Channels: From Target to Compound Identification (Q38726402) (← links)
• Voltage-gated sodium channel Nav 1.7 promotes gastric cancer progression through MACC1-mediated upregulation of NHE1. (Q38751561) (← links)
• Sodium Channels in Pain and Cancer: New Therapeutic Opportunities (Q38751843) (← links)
• Antihyperalgesic effect by herpes vector-mediated knockdown of NaV1.7 sodium channels after skin incision (Q38754033) (← links)
• HCN2 ion channels: basic science opens up possibilities for therapeutic intervention in neuropathic pain. (Q38821912) (← links)
• Pain transduction: a pharmacologic perspective (Q38823502) (← links)
• Alleviation of pain in painful diabetic neuropathy (Q38826512) (← links)
• Voltage-Gated Ion Channels in the PNS: Novel Therapies for Neuropathic Pain? (Q38846196) (← links)
• Discovery of functional monoclonal antibodies targeting G-protein-coupled receptors and ion channels (Q38860899) (← links)
• Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation (Q38938043) (← links)
• Itch in Atopic Dermatitis Management. (Q38941818) (← links)
• Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models. (Q38966383) (← links)
• Neural circuits for pain: Recent advances and current views. (Q38998006) (← links)
• Voltage-gated sodium channels and pain-related disorders (Q38999188) (← links)
• Visceral and somatic pain modalities reveal NaV 1.7-independent visceral nociceptive pathways (Q39010857) (← links)
• NaV1.7 as a pain target - From gene to pharmacology. (Q39029029) (← links)
• COL6A5 variants in familial neuropathic chronic itch. (Q39161394) (← links)
• Switching off pain at the source: is this the end for opioid pain relief? (Q39179183) (← links)
• Biologics in the treatment of chronic pain: a new era of therapy? (Q39194391) (← links)
• Progress and challenges in the optimization of toxin peptides for development as pain therapeutics (Q39219712) (← links)
• Single Residue Substitutions That Confer Voltage-Gated Sodium Ion Channel Subtype Selectivity in the NaV1.7 Inhibitory Peptide GpTx-1. (Q39987073) (← links)
• Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice. (Q40459663) (← links)
• Inflammatory Pain Reduces C Fiber Activity-Dependent Slowing in a Sex-Dependent Manner, Amplifying Nociceptive Input to the Spinal Cord. (Q41024387) (← links)
• Addition of a single methyl group to a small molecule sodium channel inhibitor introduces a new mode of gating modulation (Q41842140) (← links)
• [EXPRESS] Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications (Q46156381) (← links)
• Transplanted Human Stem Cell-Derived Interneuron Precursors Mitigate Mouse Bladder Dysfunction and Central Neuropathic Pain after Spinal Cord Injury (Q46158973) (← links)
• Engineering Antibody Reactivity for Efficient Derivatization to Generate NaV1.7 Inhibitory GpTx-1 Peptide-Antibody Conjugates. (Q46198482) (← links)
• Expression and Role of Voltage-Gated Sodium Channels in Human Dorsal Root Ganglion Neurons with Special Focus on Nav1.7, Species Differences, and Regulation by Paclitaxel (Q46380475) (← links)
• The Science of Local Anesthesia: Basic Research, Clinical Application, and Future Directions (Q47226122) (← links)
• From Mechanism to Cure: Renewing the Goal to Eliminate the Disease of Pain (Q47566382) (← links)
• Natural product modulators of human sensations and mood: molecular mechanisms and therapeutic potential (Q47652702) (← links)
• Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies. (Q47732599) (← links)
• Bulleyaconitine A preferably reduces tetrodotoxin-sensitive sodium current in uninjured dorsal root ganglion neurons of neuropathic rats probably via inhibition of protein kinase C. (Q47796198) (← links)
• Anion exchanger 3 in dorsal root ganglion contributes to nerve injury-induced chronic mechanical allodynia and thermal hyperalgesia. (Q47848159) (← links)
• Role of 5-HT5A and 5-HT1B/1D receptors in the antinociception produced by ergotamine and valerenic acid in the rat formalin test (Q47876640) (← links)
• CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide (Q47950985) (← links)
• Bromodomain-containing Protein 4 Activates Voltage-gated Sodium Channel 1.7 Transcription in Dorsal Root Ganglia Neurons to Mediate Thermal Hyperalgesia in Rats. (Q47955909) (← links)
• FGF13 Selectively Regulates Heat Nociception by Interacting with Nav1.7. (Q47984394) (← links)
• Modulatory features of the novel spider toxin μ-TRTX-Df1a isolated from the venom of the spider Davus fasciatus. (Q48100659) (← links)
• Depolarized inactivation overcomes impaired activation to produce DRG neuron hyperexcitability in a Nav1.7 mutation in a patient with distal limb pain. (Q48215989) (← links)
• Functionalized Fullerene Targeting Human Voltage-Gated Sodium Channel, hNav1.7. (Q48320854) (← links)
• A Functional NaV1.7-NaVAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site (Q48743790) (← links)
• The genetics of chronic itch: gene expression in the skin of atopic dermatitis and psoriasis patients with severe itch (Q50114014) (← links)
• Unusual Voltage-Gated Sodium Currents as Targets for Pain. (Q51537937) (← links)
• Selective Ligands and Drug Discovery Targeting the Voltage-Gated Sodium Channel Nav1.7. (Q52659071) (← links)
• Etiology and Pharmacology of Neuropathic Pain. (Q52676439) (← links)
• Enhancing inactivation rather than reducing activation of Nav1.7 channels by a clinically effective analgesic CNV1014802. (Q52746542) (← links)
• Allosteric modulation as a unifying mechanism for receptor function and regulation. (Q53082766) (← links)
• Kinetic Analysis of Membrane Potential Dye Response to NaV1.7 Channel Activation Identifies Antagonists with Pharmacological Selectivity against NaV1.5. (Q53179210) (← links)
• Persistent ERK activation by the histamine H4 receptor in spinal neurons underlies chronic itch. (Q53445962) (← links)
• Antipruritic Effects of Botulinum Neurotoxins. (Q55080639) (← links)
• Bulleyaconitine A attenuates hyperexcitability of dorsal root ganglion neurons induced by spared nerve injury: The role of preferably blocking Nav1.7 and Nav1.3 channels. (Q55209407) (← links)
• Progress in automating patch clamp cellular physiology (Q57988040) (← links)
• Itch: From mechanism to (novel) therapeutic approaches (Q58556326) (← links)
• CRMP2 and voltage-gated ion channels: potential roles in neuropathic pain (Q58582878) (← links)
• Modulating ion channel function with antibodies and nanobodies (Q58639501) (← links)
• The Na1.7 Channel Subtype as an Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons (Q58764681) (← links)
• Increased Na1.7 expression in the dorsal root ganglion contributes to pain hypersensitivity after plantar incision in rats (Q59360681) (← links)
• The Role of Voltage-Gated Sodium Channels in Pain Signaling (Q62721727) (← links)
• Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment (Q64039486) (← links)
• Defining the Functional Role of Na1.7 in Human Nociception (Q64058142) (← links)
• Antibodies and venom peptides: new modalities for ion channels (Q64076290) (← links)
• SMN deficiency causes pain hypersensitivity in a mild SMA mouse model through enhancing excitability of nociceptive dorsal root ganglion neurons (Q64095670) (← links)
• Structures of human Nav1.7 channel in complex with auxiliary subunits and animal toxins (Q68713314) (← links)
• Voltage-gated sodium channels (Q85310621) (← links)
• Analgesia: anti-itch and anti-ouch antibody (Q87407320) (← links)
• An SCN9A variant, known to cause pain, is now found to cause itch (Q88035706) (← links)
• Modulation of sodium channels as pharmacological tool for pain therapy-highlights and gaps (Q88153151) (← links)
• Peripheral and Central Mechanisms of Itch (Q88557340) (← links)
• PF-06526290 can both enhance and inhibit conduction through voltage-gated sodium channels (Q88785375) (← links)
• Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain (Q88919604) (← links)
• Identification of WB4101, an α1-Adrenoceptor Antagonist, as a Sodium Channel Blocker (Q89047014) (← links)
• Diagnosis and Management of Neuropathic Itch (Q89180162) (← links)
• Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery Strategies (Q89208053) (← links)
• Complementary roles of murine NaV1.7, NaV1.8 and NaV1.9 in acute itch signalling (Q89664859) (← links)
• Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers (Q89762760) (← links)
• Neuropathic itch (Q90128954) (← links)
• Ion Channel Targeting with Antibodies and Antibody Fragments for Cancer Diagnosis (Q90211983) (← links)
• Treatment of chronic pain by designer cells controlled by spearmint aromatherapy (Q90253945) (← links)
• Ion channels as therapeutic antibody targets (Q90335558) (← links)
• GpTx-1 and [Ala5 , Phe6 , Leu26 , Arg28 ]GpTx-1, two peptide NaV 1.7 inhibitors: analgesic and tolerance properties at the spinal level (Q90750515) (← links)
• Brucine alleviates neuropathic pain in mice via reducing the current of the sodium channel (Q90836699) (← links)
• Chronic itch management: therapies beyond those targeting the immune system (Q91237779) (← links)
• Screening Strategies for the Discovery of Ion Channel Monoclonal Antibodies (Q91247854) (← links)
• C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system (Q91256957) (← links)
• The role of Nav1.7 and methylglyoxal-mediated activation of TRPA1 in itch and hypoalgesia in a murine model of type 1 diabetes (Q91725238) (← links)
• 3'-O-Methylorobol Inhibits the Voltage-Gated Sodium Channel Nav1.7 with Anti-Itch Efficacy in A Histamine-Dependent Itch Mouse Model (Q91726406) (← links)
• Treatments for chronic pruritus outside of the box (Q91924043) (← links)
• Voltage-gated sodium channel 1.7 expression decreases in dorsal root ganglia in a spinal nerve ligation neuropathic pain model (Q92011277) (← links)
• Voltage-gated Sodium Channels and Blockers: An Overview and Where Will They Go? (Q92033630) (← links)
• A dual role for peripheral GDNF signaling in nociception and cardiovascular reflexes in the mouse (Q92058003) (← links)
• Physiology and Pathophysiology of Itch (Q92204713) (← links)
• Comprehensive engineering of the tarantula venom peptide huwentoxin-IV to inhibit the human voltage-gated sodium channel hNav1.7. (Q92216608) (← links)
• Engineering NaV1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance Pharmacokinetics (Q92387815) (← links)
• Itch Processing in the Skin (Q92409489) (← links)
• Bulleyaconitine A Inhibits Itch and Itch Sensitization Induced by Histamine and Chloroquine (Q92628099) (← links)
• A New Generation of Treatments for Itch (Q92656919) (← links)
• Pharmacological characterization of a rat Nav1.7 loss-of-function model with insensitivity to pain (Q92914001) (← links)
• Monoclonal Antibodies Targeting Ion Channels and Their Therapeutic Potential (Q92970120) (← links)
• TLR8 and its endogenous ligand miR-21 contribute to neuropathic pain in murine DRG (Q93221565) (← links)
• Molecular basis involved in the blocking effect of antidepressant metergoline on C-type inactivation of Kv1.4 channel (Q93349572) (← links)
• Current and emerging systemic treatments targeting the neural system for chronic pruritus (Q96222053) (← links)
• Retraction Notice to: A Monoclonal Antibody that Targets a NaV1.7 Channel Voltage Sensor for Pain and Itch Relief (Q96693693) (← links)
• Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch (Q97561740) (← links)
• Affinity for the Interface Underpins Potency of Antibodies Operating In Membrane Environments (Q98567648) (← links)
• Foxo1 selectively regulates static mechanical pain by interacting with Nav1.7. (Q99637064) (← links)
• Neurological Disturbances of Ciguatera Poisoning: Clinical Features and Pathophysiological Basis (Q100690362) (← links)
• Fifteen years of NaV 1.7 as an analgesic target: why has excellent in vitropharmacology not translated into in vivo analgesic efficacy? (Q102148824) (← links)
• Cutaneous gene expression in primates with itch (Q104511512) (← links)
• The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients (Q104614003) (← links)